Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4778223
Max Phase: Preclinical
Molecular Formula: C74H104N18O25
Molecular Weight: 1645.75
Molecule Type: Unknown
Associated Items:
ID: ALA4778223
Max Phase: Preclinical
Molecular Formula: C74H104N18O25
Molecular Weight: 1645.75
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCCCCCCCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H]1CNC(=O)[C@@H](CC(=O)c2ccccc2N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)[C@H]2CCCCN2C1=O
Standard InChI: InChI=1S/C74H104N18O25/c1-3-4-5-6-7-8-9-23-57(96)82-46(28-39-34-78-43-20-13-11-17-40(39)43)69(112)88-48(30-56(77)95)70(113)90-51(33-62(104)105)71(114)91-52-35-79-64(107)47(29-55(94)41-18-10-12-19-42(41)76)87-67(110)45(24-25-59(98)99)84-72(115)53(37-93)83-58(97)36-80-65(108)49(31-60(100)101)86-63(106)38(2)81-68(111)50(32-61(102)103)89-66(109)44(21-16-26-75)85-73(116)54-22-14-15-27-92(54)74(52)117/h10-13,17-20,34,38,44-54,78,93H,3-9,14-16,21-33,35-37,75-76H2,1-2H3,(H2,77,95)(H,79,107)(H,80,108)(H,81,111)(H,82,96)(H,83,97)(H,84,115)(H,85,116)(H,86,106)(H,87,110)(H,88,112)(H,89,109)(H,90,113)(H,91,114)(H,98,99)(H,100,101)(H,102,103)(H,104,105)/t38-,44+,45+,46+,47-,48-,49+,50+,51+,52+,53-,54-/m1/s1
Standard InChI Key: OOMRGJFUDQGGCI-ZLMJGSOKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1645.75 | Molecular Weight (Monoisotopic): 1644.7420 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kleijn LH,Oppedijk SF,'t Hart P,van Harten RM,Martin-Visscher LA,Kemmink J,Breukink E,Martin NI. (2016) Total Synthesis of Laspartomycin C and Characterization of Its Antibacterial Mechanism of Action., 59 (7): [PMID:26967152] [10.1021/acs.jmedchem.6b00219] |
Source(1):